On April 11, Foley partner David Rosen, co-chair of the firm’s FDA Practice Group and former FDA/CDER Senior Offical, will be speaking on the panel “Florida’s Gamble to Lower Prescription Drug Prices with Canadian Imports: Will Other States Follow or Will It Backfire?” at the New York State Bar Association’s Food, Drug & Cosmetic Law Section 2024 Spring Meeting.

What will the health care/life science legal landscape look like in 2024?

With the rise of personalized medicine, digital therapeutics and AI, we can expect new laws and regulations governing these healthcare innovations. The U.S. Food & Drug Administration (FDA) and the U.S. Federal Trade Commission (FTC) have expanded their oversight of cosmetics and health claims, respectively. We await the Supreme Court opinion on who has standing to challenge FDA drug approvals, and the possible avalanche of challenges if the appellate court definition is affirmed.